On March 27, 2014, Cytokinetics, Inc. (NASDAQ:CYTK) issued a press release announcing the initiation of an additional Phase I clinical trial of CK-2127107, a fast skeletal muscle troponin activator. Cytokinetics, Inc. (NASDAQ:CYTK) shares after opening at $8.95 moved to $9.94 on last trade day and at the end of the day closed at $9.90. Company price to sales ratio in past twelve months was calculated as 11.67 and price to cash ratio as 4.60. Cytokinetics, Inc. (NASDAQ:CYTK) showed a positive weekly performance of 2.70%.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) announced on 7 April that poster presentations related to studies with ganetespib, a selective Hsp90 inhibitor in clinical development by the company, and the company’s Hsp90 inhibitor drug conjugates (HDC) will be presented at the 2014 Annual Meeting of the American Association of Cancer Research in San Diego, California. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) shares advanced 10.07% in last trading session and ended the day on $4.48. SNTA return on equity ratio is recorded as -231.70% and its return on assets is -112.90%. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) yearly performance is -57.13%.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) on 7 April reported results of preclinical studies evaluating the anti-tumor activity of CDX-014 against a variety of cell lines. Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares moved up 9.18% in last trading session and was closed at $17.00, while trading in range of $15.66 – $17.07. Celldex Therapeutics, Inc. (NASDAQ:CLDX) year to date (YTD) performance is -29.78%.
Inovio Pharmaceuticals Inc. (NYSEMKT:INO) on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 2245.1% when compared to the same quarter one year ago, falling from -$0.66 million to -$15.45 million. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) weekly performance is -9.80%. On last trading day company shares ended up $3.13. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) distance from 50-day simple moving average (SMA50) is -1.37%. Analysts mean target price for the company is $4.60.
Leave a Reply